Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study

Wook Lee, Jong; Sicre de Fontbrune, Flore; Wong Lee Lee, Lily; Pessôa, Viviani; Fátima Menosi Gualandro, Sandra; Füreder, Wolfgang; В. Птушкин, В.; T. Rottinghaus, Scott; Volles, Lori; Shafner, Lori; Aguzzi, Rasha; Pradhan, Rajendra; Schrezenmeier, Hubert; Hill, Anita

doi:10.1182/blood-2018-09-876136

Public

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study

Published in Blood • Dec 3, 2018

Authors:

Jong Wook Lee

Flore Sicre de Fontbrune

Lily Wong Lee Lee

Abstract

Abstract Ravulizumab (ALXN1210), a new complement C5 inhibitor, provides immediate, complete, and sustained C5 inhibition. This phase 3, open-label study assessed the noninferiority of ravulizumab to eculizumab in complement inhibitor–naive adults with paroxysmal nocturnal hemoglobinuria (PNH). Pati...

Subject

Eculizumab

Paroxysmal nocturnal hemoglobinuria

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!